Dyskinesia after fetal cell transplantation for parkinsonism: A PET study

Annals of Neurology

Volumn 52, Issue 5, 2002, Pages 628-634

  Ma, Yilong ^a,b   Feigin, Andrew ^a,b   Dhawan, Vijay ^a,b   Fukuda, Masafumi ^a   Shi, Qiuhu ^c   Greene, Paul ^d   Breeze, Robert ^e   Fahn, Stanley ^d   Freed, Curt ^e   Eidelberg, David ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c North Shore Long Island Jewish Research Institute ^*  (United States)

^d Columbia College of Physicians and Surgeons ^*  (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUORINE 18;

ADULT; AGE; ARTICLE; CAUDATE NUCLEUS; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE DURATION; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DYSKINESIA; FETUS CELL; FOLLOW UP; HUMAN; HUMAN CELL; NERVE CELL; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADULT; BRAIN; CAUDATE NUCLEUS; COHORT STUDIES; DIHYDROXYPHENYLALANINE; DOUBLE-BLIND METHOD; DYSKINESIAS; FETAL TISSUE TRANSPLANTATION; FLUORINE RADIOISOTOPES; HUMANS; MIDDLE AGED; PARKINSONIAN DISORDERS; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036830588     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10359     Document Type: Article

References (22)

1. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Eng J Med 2001;344:710-719.
2. Greene PE, Fahn S, Tsai WY. Severe spontaneous dyskinesias: A disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov Disord 1999;14:904.
3. Brundin P, Dunnett S, Bjorklund A, Nikkhah G. Transplanted dopaminergic neurons: More or less? Nat Med 2001;7:512-513.
4. Freed CR, Breeze RE, Greene P, et al. Transplanted dopaminergic neurons: More or less? Nat Med 2001;7:512-513.
5. Remy P, Samson Y, Hantraye P, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995;38:580-588.
6. Wenning G, Oden P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997;42:95-107.
7. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179-187.
8. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001;50:181-187.
9. Fahn S, Elton R. Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. New York: Macmillan, 1987:293-304.
10. Dhawan V, Kazumata K, Robeson W, et al. Quantitative brain PET: Comparison of 2D and 3D acquisition on the GE Advance Scanner. Clin Positron Imaging 1998;1:135-144.
11. Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med 1996;37:216-222.
12. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: SOR verses Ki. J Cereb Blood Flow Metab 2001;21:S534.
13. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
14. Gerfen CR. Molecular effects of dopamine on striatalprojection pathways. Trends Neurosci 2000;23:S64-S70.
15. Alexander GE, DeLong MR. Microstimulation of the primate neo striatum. II. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J Neurophysiol 1985;53:1417-1430.
16. Maillard L, Ishii K, Bushara K, et al. Mapping the basal ganglia: fMRI evidence for somatotopic representation of face, hand, and foot. Neurology 2000;55:377-383.
17. Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopainduced dyskinesias in Parkinson's disease: Phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
18. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol 1978;35:261-263.
19. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2-S11.
20. Alexander GE, DeLong MR. Microstimulation of the primate neostriatum. I. Physiological properties of striatal microexcitable zones. J Neurophysiol 1985;53:1401-1416.
21. Isacson O, Bjorklund L, Pernaute RS. Parkinson's disease: Interpretations of transplantation study are erroneous. Nat Neurosci 2001;4:553.
22. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-628.